399 related articles for article (PubMed ID: 30541855)
1. Human Norovirus Neutralized by a Monoclonal Antibody Targeting the Histo-Blood Group Antigen Pocket.
Koromyslova AD; Morozov VA; Hefele L; Hansman GS
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541855
[TBL] [Abstract][Full Text] [Related]
2. Broadly cross-reactive human antibodies that inhibit genogroup I and II noroviruses.
Alvarado G; Salmen W; Ettayebi K; Hu L; Sankaran B; Estes MK; Venkataram Prasad BV; Crowe JE
Nat Commun; 2021 Jul; 12(1):4320. PubMed ID: 34262046
[TBL] [Abstract][Full Text] [Related]
3. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity.
Debbink K; Donaldson EF; Lindesmith LC; Baric RS
J Virol; 2012 Jan; 86(2):1214-26. PubMed ID: 22090110
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of GII.4 norovirus persistence in human populations.
Lindesmith LC; Donaldson EF; Lobue AD; Cannon JL; Zheng DP; Vinje J; Baric RS
PLoS Med; 2008 Feb; 5(2):e31. PubMed ID: 18271619
[TBL] [Abstract][Full Text] [Related]
5. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation.
Lindesmith LC; Beltramello M; Donaldson EF; Corti D; Swanstrom J; Debbink K; Lanzavecchia A; Baric RS
PLoS Pathog; 2012; 8(5):e1002705. PubMed ID: 22615565
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis for Human Norovirus Capsid Binding to Bile Acids.
Kilic T; Koromyslova A; Hansman GS
J Virol; 2019 Jan; 93(2):. PubMed ID: 30355683
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of antibody-binding epitopes on the norovirus GII.3 capsid.
Mahar JE; Donker NC; Bok K; Talbo GH; Green KY; Kirkwood CD
J Virol; 2014 Feb; 88(4):1942-52. PubMed ID: 24284328
[TBL] [Abstract][Full Text] [Related]
8. Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigens.
Parra GI; Abente EJ; Sandoval-Jaime C; Sosnovtsev SV; Bok K; Green KY
J Virol; 2012 Jul; 86(13):7414-26. PubMed ID: 22532688
[TBL] [Abstract][Full Text] [Related]
9. Human noroviruses' fondness for histo-blood group antigens.
Singh BK; Leuthold MM; Hansman GS
J Virol; 2015 Feb; 89(4):2024-40. PubMed ID: 25428879
[TBL] [Abstract][Full Text] [Related]
10. Structural Basis of Nanobodies Targeting the Prototype Norovirus.
Ruoff K; Kilic T; Devant J; Koromyslova A; Ringel A; Hempelmann A; Geiss C; Graf J; Haas M; Roggenbach I; Hansman G
J Virol; 2019 Mar; 93(6):. PubMed ID: 30602609
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002.
Lindesmith LC; Debbink K; Swanstrom J; Vinjé J; Costantini V; Baric RS; Donaldson EF
J Virol; 2012 Jan; 86(2):873-83. PubMed ID: 22090098
[TBL] [Abstract][Full Text] [Related]
12. Identification of Human Norovirus GII.3 Blockade Antibody Epitopes.
Yi Y; Wang S; Wang X; Xiong P; Liu Q; Zhang C; Yin F; Huang Z
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696487
[TBL] [Abstract][Full Text] [Related]
13. Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera.
Malm M; Tamminen K; Vesikari T; Blazevic V
Viral Immunol; 2018 Dec; 31(10):649-657. PubMed ID: 30431404
[TBL] [Abstract][Full Text] [Related]
14. Norovirus GII.4 strain antigenic variation.
Lindesmith LC; Donaldson EF; Baric RS
J Virol; 2011 Jan; 85(1):231-42. PubMed ID: 20980508
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody.
Shanker S; Czakó R; Sapparapu G; Alvarado G; Viskovska M; Sankaran B; Atmar RL; Crowe JE; Estes MK; Prasad BV
Proc Natl Acad Sci U S A; 2016 Oct; 113(40):E5830-E5837. PubMed ID: 27647885
[TBL] [Abstract][Full Text] [Related]
16. Structural analysis of histo-blood group antigen binding specificity in a norovirus GII.4 epidemic variant: implications for epochal evolution.
Shanker S; Choi JM; Sankaran B; Atmar RL; Estes MK; Prasad BV
J Virol; 2011 Sep; 85(17):8635-45. PubMed ID: 21715503
[TBL] [Abstract][Full Text] [Related]
17. Direct Blockade of the Norovirus Histo-Blood Group Antigen Binding Pocket by Nanobodies.
Kher G; Sabin C; Lun JH; Devant JM; Ruoff K; Koromyslova AD; von Itzstein M; Pancera M; Hansman GS
J Virol; 2023 Apr; 97(4):e0183322. PubMed ID: 36971561
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of GII.10 and GII.12 norovirus protruding domains in complex with histo-blood group antigens reveal details for a potential site of vulnerability.
Hansman GS; Biertümpfel C; Georgiev I; McLellan JS; Chen L; Zhou T; Katayama K; Kwong PD
J Virol; 2011 Jul; 85(13):6687-701. PubMed ID: 21525337
[TBL] [Abstract][Full Text] [Related]
19. Bile Facilitates Human Norovirus Interactions with Diverse Histoblood Group Antigens, Compensating for Capsid Microvariation Observed in 2016-2017 GII.2 Strains.
Mallory ML; Lindesmith LC; Brewer-Jensen PD; Graham RL; Baric RS
Viruses; 2020 Sep; 12(9):. PubMed ID: 32899556
[TBL] [Abstract][Full Text] [Related]
20. Human Norovirus Epitope D Plasticity Allows Escape from Antibody Immunity without Loss of Capacity for Binding Cellular Ligands.
Lindesmith LC; Brewer-Jensen PD; Mallory ML; Yount B; Collins MH; Debbink K; Graham RL; Baric RS
J Virol; 2019 Jan; 93(2):. PubMed ID: 30355694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
